



Published: December 2013

Single User PDF: **US\$ 2000**

Corporate User PDF: US\$ 6000

Inquire for Discount















Researcher's report, "Gaucher"s Disease - Pipeline Review, H2 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for **Gaucher's Disease**, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gaucher"s Disease. Gaucher"s Disease - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team.

Complete Report of 78 pages is available @ http://www.reportsnreports.com/reports/273682-gauchers-disease-pipeline-review-h2-2013.html .

Scope

- A snapshot of the global therapeutic scenario for Gaucher's Disease.
- A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.





- -A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gaucher''s Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=273682.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counterstrategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

ReportsnReports



Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Gaucher''s Disease Overview 8

Therapeutics Development 9

Pipeline Products for Gaucher''s Disease - Overview 9

Pipeline Products for Gaucher''s Disease - Comparative Analysis 10

Gaucher''s Disease - Therapeutics under Development by Companies 11

Gaucher''s Disease - Therapeutics under Investigation by Universities/Institutes 13

Gaucher''s Disease - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Gaucher''s Disease - Products under Development by Companies 18

Gaucher''s Disease - Products under Investigation by Universities/Institutes 19





List of Tables

Number of Products under Development for Gaucher"s Disease, H2 2013 9

Number of Products under Development for Gaucher's Disease - Comparative Analysis, H2 2013 10

Number of Products under Development by Companies, H2 2013 12

Number of Products under Investigation by Universities/Institutes, H2 2013 13

Comparative Analysis by Late Stage Development, H2 2013 14

Comparative Analysis by Clinical Stage Development, H2 2013 15

Comparative Analysis by Early Stage Development, H2 2013 16

Comparative Analysis by Unknown Stage Development, H2 2013 17

Products under Development by Companies, H2 2013 18

Products under Investigation by Universities/Institutes, H2 2013 19

Gaucher''s Disease - Pipeline by Genzyme Corporation, H2 2013 20

Gaucher''s Disease - Pipeline by Amicus Therapeutics, Inc., H2 2013 21

Gaucher''s Disease - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2013 22

Gaucher''s Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2013 23

Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on "Gaucher's Disease - Pipeline Review, H2 2013" report OR for any other market research and intelligence needs you may have for your business.